Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization.
about
Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myelomaCyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma.Effectiveness of etoposide chemomobilization in lymphoma patients undergoing auto-SCT.Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation.Novel strategies for blood stem cell mobilization: special focus on plerixafor.How we mobilize haemopoietic stem cells.Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.Novel agents and approaches for stem cell mobilization in normal donors and patients.Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept.Increased mobilization and yield of stem cells using plerixafor in combination with granulocyte-colony stimulating factor for the treatment of non-Hodgkin's lymphoma and multiple myeloma.A plerixafor-based strategy allows adequate hematopoietic stem cell collection in poor mobilizers: results from the Canadian Special Access Program.Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.The effective use of plerixafor as a real-time rescue strategy for patients poorly mobilizing autologous CD34(+) cells.Mobilization of hematopoietic progenitor cells for autologous transportation: consensus recommendations.Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency.Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study.New strategies for stem cell mobilization.G-CSF plus preemptive plerixafor vs hyperfractionated CY plus G-CSF for autologous stem cell mobilization in multiple myeloma: effectiveness, safety and cost analysis.Mobilization and transplantation patterns of autologous hematopoietic stem cells in multiple myeloma and non-Hodgkin lymphoma.Blood graft composition after plerixafor injection in patients with NHL.Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.A phase I study of intravenous plerixafor following cyclophosphamide mobilization in patients with multiple myeloma.Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies.Cost-effectiveness of on-demand plerixafor added to chemotherapy and granulocyte-colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma.Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure.Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis.Hematopoietic stem cell mobilizing agents G-CSF, cyclophosphamide or AMD3100 have distinct mechanisms of action on bone marrow HSC niches and bone formation.
P2860
Q24186469-15A992B4-030C-4792-95BF-D02A0AE5AA62Q35911212-6523ADE3-0F83-4E8E-885D-4EE0C377D60CQ35965373-F00C33B5-E2CA-45C2-954E-4876CC6F0674Q35994520-95C18896-2BA1-4A2A-8166-6C2DE0A42AA0Q37909447-CD764BD4-E523-4AE3-9167-8D7CA252CC6AQ37914921-6EEF60E0-15F7-4160-B762-EFAC43E6B734Q37921284-27DA33E2-7A09-4E18-A0F3-6F68FCB6D53FQ37923309-B47409B9-339B-4048-8CDD-322DD57ACA6CQ37943423-17190B85-BAAB-4B3B-B89C-EE20AD33AC31Q38160461-1D42A11C-92A0-40EC-A570-B85725552FD7Q38194916-A2FAE626-5D77-48C6-BA7C-4867842E9DBFQ38200909-83F2A103-82C8-4CCA-B783-BC69345A18D6Q39049318-AFEA7801-51B3-498B-9FEE-D1B27F9811B3Q40407349-11E2BBA7-E66F-415D-9CDD-0FDD8475730CQ40543905-3D8B809B-09D8-4401-B3B0-B58D3B5A8535Q41003137-C49322FB-34C3-4758-ABCE-9563FB80C7B1Q41104670-76D06BE4-0BE2-44E8-9DD3-0837DE321A34Q41267193-5D49DA6C-0357-44C8-81B4-1E735715BCE6Q41694417-57623844-93E9-4D16-AA0C-905105B29E35Q44353274-5A33FC2B-CBF0-41FE-BF16-805F5D93EF6BQ44986060-F7634DE4-94C3-4A1C-B097-41507681B1CAQ45248410-39109A5B-3EB1-47E6-877B-91CE7FBA4118Q46877033-A54D2FC8-4FD2-4359-A3FC-BE7CE7465EC8Q48337454-6808C189-05EB-4CAB-8BE1-1A5ACEB4B10BQ51385709-A4F5222A-3D2E-45DF-B6C0-8E695B4BF5AAQ51405815-142765C4-50A9-4D94-8FE4-1286D1DAD06AQ54327926-B72894CA-656B-40B0-8971-7D35E5339DFC
P2860
Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Growth factor and patient-adap ...... ietic stem cells mobilization.
@en
Growth factor and patient-adap ...... ietic stem cells mobilization.
@nl
type
label
Growth factor and patient-adap ...... ietic stem cells mobilization.
@en
Growth factor and patient-adap ...... ietic stem cells mobilization.
@nl
prefLabel
Growth factor and patient-adap ...... ietic stem cells mobilization.
@en
Growth factor and patient-adap ...... ietic stem cells mobilization.
@nl
P2093
P2860
P356
P1476
Growth factor and patient-adap ...... ietic stem cells mobilization.
@en
P2093
P2860
P2888
P304
P356
10.1038/BMT.2010.170
P407
P577
2010-07-12T00:00:00Z